Potential Benefits of Experimental Dementia Drug in Alcohol Withdrawal

Researchers at the University of Kentucky have found that an investigational dementia medication might assist in easing alcohol withdrawal by calming brain inflammation associated with addiction and relapse. The drug, known as MW150, targets a brain inflammation pathway called p38α MAPK and is intended to treat mild to moderate Alzheimer’s disease.

Scientific studies suggest that neuroinflammation may increase the risk of relapse and cause long-term neurological damage in individuals suffering from alcohol use disorder. In laboratory and animal experiments, MW150 showed a reduction in inflammatory markers during alcohol withdrawal. This research was conducted at the University of Kentucky’s Sanders-Brown Center on Aging and led by neuroinflammation expert Linda Van Eldik.

Dr. Caleb Bailey, a co-author of the study, believes MW150 offers a potential method to lessen neuroinflammation due to alcohol withdrawal. Alcohol use disorder is challenging to treat because of high relapse rates, particularly during withdrawal. If future experiments demonstrate similar anti-inflammatory effects in animal models, the development of MW150 as a treatment for chronic alcohol relapse could be strongly supported.

In addition to MW150, a related drug called Neflamapimod is being tested in clinical trials for dementia and other neurodegenerative conditions. The fact that these compounds are already advancing in development for neurological diseases adds significance, as they may be repurposed for alcohol-related conditions if further research yields promising results.

There are important limitations to the research, as it was performed on cell culture and animal models, which offer limited insights into the full organism’s responses. According to Bailey, further studies in living animals are required to understand how MW150 treatment influences systemic health and alcohol consumption during withdrawal.

Dr. Amy Swift, deputy chief medical officer at Silver Hill Hospital in Connecticut, who was not involved in the study, shared her thoughts on the findings. Detoxification with tapering medication doses is considered the first evidence-based step in treating alcohol use disorder, but its impact on long-term drinking behavior is limited. Detoxification prevents potentially fatal complications of alcohol withdrawal but does not address the disorder itself.

Swift proposes that supportive medications enhancing overall brain health could fill a critical gap in early detoxification treatment. Exploring whether reducing neuroinflammation could help patients engage in treatment earlier in recovery and improve their long-term relationship with alcohol is worthwhile. Given alcohol’s significant inflammatory impacts on various organ systems, this approach could be beneficial.

Bailey emphasizes that no level of alcohol consumption is beneficial to physical health. Currently, there are no robust pharmacological treatments to mitigate the damage from chronic alcohol consumption, so minimizing alcohol intake remains the best strategy for maintaining health. As MW150 continues to be studied in dementia patients, understanding its interaction with alcohol will be crucial for patient outcomes.